- A presentation at the 2024
Leerink Partners Global Biopharma Conference at8:40 a.m. ET onWednesday, March 13, 2024 inMiami, FL - A fireside chat at the H.C. Wainwright 2nd Annual
Cell Therapy Virtual Conference at11:00 a.m. ET onTuesday, March 26, 2024
A live webcast of the presentation and fireside chat are expected to be accessible in the Events section of the Company’s website at www.cartesiantherapeutics.com, where an archived replay of the events will also be available for a limited time.
About Cartesian Therapeutics
Cartesian Therapeutics is a clinical-stage company pioneering mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a potential first-in-class mRNA CAR-T in Phase 2b clinical development for patients with generalized myasthenia gravis. Additional Phase 2 studies are planned in systemic lupus erythematosus under an allowed IND, as well as basket trials in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA mRNA CAR-T. Cartesian operates a wholly owned, state-of-the-art cGMP manufacturing facility in
Contact Information:
Investor Relations:
Melissa Forst
cartesian@argotpartners.com
Media:
david.rosen@argotpartners.com
Source:
2024 GlobeNewswire, Inc., source